1. Search Result
Search Result
Results for "

vancomycin

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

1

Screening Libraries

1

Biochemical Assay Reagents

4

Peptides

1

Inhibitory Antibodies

15

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0671
    Vancomycin
    Maximum Cited Publications
    51 Publications Verification

    Bacterial Autophagy Antibiotic Infection Cancer
    Vancomycin is an antibiotic for the treatment of bacterial infections.
    Vancomycin
  • HY-17362
    Vancomycin hydrochloride
    Maximum Cited Publications
    51 Publications Verification

    Bacterial Autophagy Antibiotic Infection Cancer
    Vancomycin hydrochloride is an antibiotic for the treatment of bacterial infections. It acts by inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin also alters the permeability of the cell membrane and selectively inhibits ribonucleic acid synthesis.
    Vancomycin hydrochloride
  • HY-105282

    MM 45289; A 82846A

    Antibiotic Bacterial Infection
    Eremomycin (MM 45289) is a potent glycopeptide antibiotic closely related to Vancomycin (HY-B0671). Eremomycin shows antibacterial activity in Staphylococcus spp. and Bacillus subtilis ATCC6633, with the MIC values of 0.03-1.6 μg/mL .
    Eremomycin
  • HY-112579
    Ceftobiprole
    2 Publications Verification

    Ro 63-9141; BAL 9141

    Bacterial Antibiotic Infection Inflammation/Immunology
    Ceftobiprole (Ro 63-9141) is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci with a MIC90 value of 2 μg/mL for MRSA. Ceftobiprole also inhibits gram-positive and gram-negative pathogens .
    Ceftobiprole
  • HY-B0671R

    Bacterial Autophagy Antibiotic Infection Cancer
    Vancomycin (Standard) is the analytical standard of Vancomycin. This product is intended for research and analytical applications. Vancomycin is an antibiotic for the treatment of bacterial infections.
    Vancomycin (Standard)
  • HY-17362R

    Bacterial Autophagy Antibiotic Infection Cancer
    Vancomycin (hydrochloride) (Standard) is the analytical standard of Vancomycin (hydrochloride). This product is intended for research and analytical applications. Vancomycin hydrochloride is an antibiotic for the treatment of bacterial infections. It acts by inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin also alters the permeability of the cell membrane and selectively inhibits ribonucleic acid synthesis.
    Vancomycin hydrochloride (Standard)
  • HY-B0671S3

    Isotope-Labeled Compounds Antibiotic Bacterial Autophagy Infection
    Vancomycin-d10 (TFA) is a deuterated labeled Vancomycin . Vancomycin is an antibiotic for the treatment of bacterial infections.
    Vancomycin-d10 TFA
  • HY-N10765

    Bacterial Inflammation/Immunology Cancer
    Salvinolone is active against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Salvinolone shows cytotoxic activity with an IC50 of 47.6 μM against the HL-60 tumor cell line for 72 h .
    Salvinolone
  • HY-N13196

    Bacterial Infection
    Arcopilin A (compound Arcopilin A(1))is an antibacterial agent. Arcopilin A has weak inhibitory effects on fungal pathogens and Gram-positive bacteria, with IC50 values of 8.9 μg/mL and 14 μg/mL for cells KB-3-1 and L929, but it can effectively destroy preformed biofilms of Staphylococcus aureus. Arcopilin A can enhance the activities of gentamicin (GM; HY-K1050) and vancomycin (Vac; HY-B0671) by 115 and 31 times, respectively .
    Arcopilin A
  • HY-161935

    Bacterial Infection Inflammation/Immunology
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid (Compound 2) exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin enterococci (VRE). 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid interfers with the integrity and function of the bacterial cell membrane, and affects metabolism in MRSA. 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid exhibits anti-inflammatory and anti-infective efficacy, and promotes angiogenesis in mice .
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid
  • HY-B1924
    Norvancomycin hydrochloride
    1 Publications Verification

    Desmethyl-vancomycin hydrochloride

    Bacterial Antibiotic Infection
    Norvancomycin hydrochloride is suitable for endocarditis, osteomyelitis, pneumonia, sepsis or soft tissue infections caused by Staphylococcus aureus (including methicillin-resistant strains and multi-drug-resistant strains).
    Norvancomycin hydrochloride
  • HY-106574

    BAL5788

    Bacterial Infection Inflammation/Immunology
    Ceftobiprole medocaril (BAL5788) is the parenteral proagent of Ceftobiprole (HY-112579). Ceftobiprole is a parenteral pyrrolidinone cephalosporin. Ceftobiprole is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci. Ceftobiprole also inhibits gram-positive and gram-negative pathogens .
    Ceftobiprole medocaril
  • HY-106574A

    BAL5788 sodium

    Bacterial Infection Inflammation/Immunology
    Ceftobiprole medocaril (BAL5788) sodium is the parenteral proagent of Ceftobiprole (HY-112579). Ceftobiprole is a parenteral pyrrolidinone cephalosporin. Ceftobiprole is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci. Ceftobiprole also inhibits gram-positive and gram-negative pathogens .
    Ceftobiprole medocaril sodium
  • HY-112959

    TD-6424

    Antibiotic Bacterial Infection
    Telavancin (TD-6424) is a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). Telavancin disrupts cell membrane integrity, can be used for research of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria .
    Telavancin
  • HY-144621

    Bacterial Infection Inflammation/Immunology
    Antibacterial agent 75 (compound 24) is an antibacterial agent. Antibacterial agent 75 (compound 24) is able to re-sensitize VRSA to vancomycin .
    Antibacterial agent 75
  • HY-121000

    Ingramycin

    Antibiotic Bacterial Infection
    Albocycline (Ingramycin) is a macrolide antibiotic, which exhibits antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin (HY-B0671)-intermediate (VISA), and Vancomycin (HY-B0671)-resistant S. aureus (VRSA) strains with MICs ranging from 0.5 to 1.0 μg/mL. Albocycline exhibits no toxicity to human cells at concentration of ≤64 μg/mL .
    Albocycline
  • HY-156198

    Antibiotic Bacterial Infection
    Bottromycin A2 is a natural antibiotic. Bottromycin A2 is active against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) .
    Bottromycin A2
  • HY-P5204

    K1-EJ hybrid

    Bacterial Infection
    Enterocin Hybrid 1 is a antibacterial agent, a antibacterial composition. Enterocin Hybrid 1 inhibits Vancomycin (HY-B0671)-resistant E. faecium, Staphylococcus haemoliticus .
    Enterocin Hybrid 1
  • HY-111071

    CG-400549

    Bacterial Antibiotic Infection Inflammation/Immunology
    Nilofabicin is an enoyl-(acyl-carrier protein) reductase (FabI) inhibitor. Nilofabicin had an MIC(90) of 0.5 microg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin .
    Nilofabicin
  • HY-164123

    Bacterial Infection
    Antibiofilm agent-9 (Compound 4) is a pyrrolomycin derivative with antibacterial activity. Antibiofilm agent-9 inhibits Bacillus anthracis with MIC of 0.031 μg/mL. Antibiofilm agent-9 exhibits antibiofilm activity with 84% biofilm inhibition (24 h, 8.0 μg/mL). Antibiofilm agent-9 exhibits a good pharmacokinetic characters in mouse model .
    Antibiofilm agent-9
  • HY-169105

    DNA/RNA Synthesis Bacterial Infection
    DNA Gyrase-IN-12 (Compound 6d) is a DNA gyrase inhibitor. DNA Gyrase-IN-12 has Antibacterial activity and MIC value of vancomycin-intermediate S. aureus (VISA) and Enterococcus faecalis strains is between 0.031 and 0.0625 μg/mL .
    DNA Gyrase-IN-12
  • HY-162782A

    Antibiotic Bacterial Infection
    V–C6–Bg-PhCl TFA (compound 5e) is a biguanide-vancomycin conjugate. V–C6–Bg-PhCl TFA has broad-spectrum antibacterial activity against both Gram-negative and Gram-positive bacteria .
    V–C6–Bg-PhCl TFA
  • HY-163399

    Bacterial Infection
    Antibacterial agent 197 (compound 1-deAA) is a termination inhibitor of non-classical anhydroglycosyl receptors and anhydrowall peptide-type peptidoglycan (PG) in bacterial TGase, with activity against Staphylococcus aureus. Antibacterial agent 197 synergizes with Vancomycin (HY-B0671) and is its antibacterial adjuvant .
    Antibacterial agent 197
  • HY-117845

    LL-E19085α

    Others Infection
    Citreamicin alpha (LL-E 19085-alpha) is an antibiotic whose in vitro antimicrobial activity against 429 clinical isolates of Gram-positive cocci has been tested by the agar dilution method. These microorganisms included 313 strains of Staphylococci and 116 strains of Streptococci. The in vitro activity of Citreamicin alpha was compared with that of ampicillin, amoxicillin, ceftriaxone, erythromycin, and vancomycin. For Staphylococci, the MIC values of Citreamicin alpha ranged from 0.12-4.0 μg/ml, and for Streptococcus pyogenes of the genus Streptococcus, it was 0.03-0.12 μg/ml. However, enterococci were relatively resistant, requiring 2.0 μg/ml of the agent to inhibit 64% of the 62 tested strains. The in vitro activity of this antibiotic was much better than that of ampicillin, amoxicillin, ceftriaxone, and erythromycin, but comparable or slightly inferior to that of vancomycin.
    Citreamicin alpha
  • HY-P3361

    Parasite Bacterial Antibiotic Infection Inflammation/Immunology
    IDR-1018 is an innate defense regulator conjugate, with MICs of 16 μg/mL for MRSA USA300 LAC, MRSA SAP 0017 and S. epidermidis ATCC14990. IDR-1018 can be used to synthesis V-IDR1018 (vancomycin-innate defense regulator conjugate) .
    IDR-1018
  • HY-P3078

    Bacterial Antibiotic Infection
    Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci .
    Amphomycin
  • HY-14849

    Razupenem; SM 216601; SMP 601

    Antibiotic Bacterial Others
    PTZ601 (SMP 601) is an antibiotic, which inhibits the gram-positive bacteria, including the Vancomycin (HY-B0671)-resistant Enterococcus faecium (VREF) and Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA). PTZ601 exhibits antimicrobial activity in infected mouse models .
    PTZ601
  • HY-161263

    Bacterial Infection
    Antibacterial agent 182 (compound 8c) is an antibacterial agent that shows antibacterial activity against various Gram-positive bacteria, particularly against Vancomycin-resistant Enterococcus faecalis (MIC ≤0.125 μg/mL). Antibacterial agent 182 inhibits biofilm formation of Staphylococcus aureus and Pseudomonas aeruginosa at sub-MIC doses .
    Antibacterial agent 182
  • HY-143326

    Bacterial Infection
    Antibacterial agent 83 (compound 17h) displays potent antibacterial activity against various vancomycin-resistant Enterococcus faecalis (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). Antibacterial agent 83 can significantly reduce the biofilm formation of MRSA and exhibited promising selectivity. Antibacterial agent 83 is metabolically stable in human liver microsomes .
    Antibacterial agent 83
  • HY-133119

    Bacterial Infection
    PK150, an analogue of Sorafenib, shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Vancomycin intermediate S. aureus (VISA) with MICs of 0.3, 0.3-1, 0.3 µM, respectively .
    PK150
  • HY-A0279

    Pristinamycine

    Bacterial Antibiotic Infection
    Pristinamycin, produced by Streptomyces pristinaespiralis, is an orally active streptogramin-like antibiotic consisting of two chemically unrelated components: Pristinamycin I (PI) and Pristinamycin II (PII). Pristinamycin is highly active against many antibiotic-resistant pathogens, particularly Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant S. aureus (VRSA) and Enterococcus faecium (VREF) .
    Pristinamycin
  • HY-N0148A
    Rutin hydrate
    10+ Cited Publications

    Rutoside hydrate; Quercetin 3-O-rutinoside hydrate

    Amyloid-β Autophagy Apoptosis Endogenous Metabolite Neurological Disease Cancer
    Rutin (Rutoside) hydrate is a flavonoid found in many plants and shows a wide range of biological activities including anti-inflammatory, antidiabetic, antioxidant, neuroprotective, nephroprotective, hepatoprotective and reducing Aβ oligomer activities. Rutin hydrate can cross the blood brain barrier. Rutin hydrate attenuates vancomycin-induced renal tubular cell apoptosis via suppression of apoptosis, mitochondrial dysfunction, and oxidative stress .
    Rutin hydrate
  • HY-16485

    TD-6424 hydrochloride

    Antibiotic Bacterial Infection
    Telavancin hydrochloride is the hydrochloride form of Telavancin (HY-112959). Telavancin hydrochloride is a semisynthetic derivative of vancomycin, and exhibits antibacterial efficacy through inhibition of cell wall synthesis and disruption of cell membrane barrier function. Telavancin hydrochloride is efficient against antibiotic resistant S. aureus strains MRSA, VISA, and hVISA. Telavancin hydrochloride attenuates gram positive bacteria induced complicated skin and skin structure infections (cSSSI) .
    Telavancin hydrochloride
  • HY-117254

    Others Infection
    BAS00127538 is a Lipid II inhibitor with antibacterial activity. As the first small molecule Lipid II inhibitor, BAS00127538 has a structure that is significantly different from compounds that naturally bind to Lipid II, such as vancomycin. The activity of BAS00127538 in terms of cytotoxicity and Lipid II binding is of great significance in antibacterial effects. Studies on BAS00127538 have shown that it has the potential to inhibit infection .
    BAS00127538
  • HY-146811

    Bacterial Inflammation/Immunology
    HSGN-94 is a potent antimicrobial agent with lipoteichoic acid (LTA) biosynthesis inhibition. HSGN-94 inhibits drug-resistant Gram-positive bacteria with MIC values of 0.25-2 μg/mL. HSGN-94 inhibits biofilm formation of MRSA and Vancomycin-resistant Enterococci. HSGN-94 also inhibits pro-inflammatory cytokines, exhibits in vivo efficacy in an MRSA murine wound infection model .
    HSGN-94
  • HY-N0148
    Rutin
    10+ Cited Publications

    Rutoside; Quercetin 3-O-rutinoside

    Amyloid-β Autophagy Apoptosis Endogenous Metabolite Inflammation/Immunology Cancer
    Rutin (Rutoside) is a flavonoid found in many plants and shows a wide range of biological activities including anti-inflammatory, antidiabetic, antioxidant, neuroprotective, nephroprotective, hepatoprotective and reducing Aβ oligomer activities. Rutin is also a CBR1 inhibitor, which can cross the blood brain barrier. Rutin attenuates vancomycin-induced renal tubular cell apoptosis via suppression of apoptosis, mitochondrial dysfunction, and oxidative stress .
    Rutin
  • HY-P99583

    MEDI4893

    Bacterial Infection Inflammation/Immunology
    Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
    Suvratoxumab
  • HY-162775

    Bacterial Antibiotic Infection
    TST1N-224 is a potent response regulator VraRC inhibitor. TST1N-224 can disrupt VraRC-DNA complex formation (IC50=60.2 μM). TST1N-224 exhibits interference with VraRC binding to its cognate DNA through a fast-on-fast-off binding mechanism (KD=23.4 μM). TST1N-224 predominantly interacts with the α9- and α10-helixes of the DNA-binding domain of VraR. TST1N-224 inhibits the growths of S. aureus (SA; MIC>126 μM), Methicillin-resistant S. aureus (MRSA; MIC>126 μM), and Vancomycin-intermediate S. aureus (VISA; MIC=63 μM). TST1N-224, an antimicrobial agent, evidently enhances the susceptibility of VISA to both Vancomycin (HY-B0671) and Methicillin (HY-B0974) .
    TST1N-224
  • HY-N0148R

    Amyloid-β Autophagy Apoptosis Endogenous Metabolite Inflammation/Immunology Cancer
    Rutin (Standard) is the analytical standard of Rutin. This product is intended for research and analytical applications. Rutin (Rutoside) is a flavonoid found in many plants and shows a wide range of biological activities including anti-inflammatory, antidiabetic, antioxidant, neuroprotective, nephroprotective, hepatoprotective and reducing Aβ oligomer activities. Rutin is also a CBR1 inhibitor, which can cross the blood brain barrier. Rutin attenuates vancomycin-induced renal tubular cell apoptosis via suppression of apoptosis, mitochondrial dysfunction, and oxidative stress .
    Rutin (Standard)
  • HY-B1831

    LY 333328; Orbactiv

    Antibiotic Bacterial Infection Inflammation/Immunology
    Oritavancin (LY 333328), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity .
    Oritavancin
  • HY-116863

    Bacterial Infection
    KKL-40 is a small molecule inhibitor that targets the trans-transcription process and is effective against methicillin-sensitive and -resistant Staphylococcus aureus (S. aureus) as well as other Gram-positive pathogens including vancomycin-resistant Enterococcus faecium, Bacillus subtilis, and Streptococcus pyogenes. KKL-40 synergizes with the human antimicrobial peptide LL-37 to inhibit S. aureus, but does not synergize with other antibiotics such as daptomycin, kanamycin, or erythromycin. Trans-transcription is an extreme form of recoding, and KKL-40 inhibits trans-transcription but is nontoxic to HeLa cells .
    KKL-40
  • HY-125745

    Antibiotic Bacterial Infection
    Loloatin B 10 is an antibiotic, which exhibits antibacterial efficacy against gram positive antibiotic resistant human pathogens .
    Loloatin B 10
  • HY-B1831A
    Oritavancin diphosphate
    1 Publications Verification

    LY333328 diphosphate

    Bacterial Antibiotic Infection Inflammation/Immunology
    Oritavancin diphosphate (LY333328 diphosphate), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin diphosphate shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin diphosphate inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin diphosphate inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin diphosphate enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity .
    Oritavancin diphosphate
  • HY-B1831AR

    Bacterial Antibiotic Infection Inflammation/Immunology
    Oritavancin (diphosphate) (Standard) is the analytical standard of Oritavancin (diphosphate). Oritavancin diphosphate (Standard), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin diphosphate (Standard) shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin diphosphate (Standard) inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin diphosphate (Standard) inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin diphosphate (Standard) enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity .
    Oritavancin diphosphate (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: